UNITY Biotechnology Inc
NASDAQ:UBX
UNITY Biotechnology Inc
Research & Development
UNITY Biotechnology Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
UNITY Biotechnology Inc
NASDAQ:UBX
|
Research & Development
-$12.1m
|
CAGR 3-Years
34%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
UNITY Biotechnology Inc
Glance View
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in Brisbane California, California and currently employs 65 full-time employees. The company went IPO on 2018-05-03. The firm is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The firm is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The firm's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.
See Also
What is UNITY Biotechnology Inc's Research & Development?
Research & Development
-12.1m
USD
Based on the financial report for Mar 31, 2025, UNITY Biotechnology Inc's Research & Development amounts to -12.1m USD.
What is UNITY Biotechnology Inc's Research & Development growth rate?
Research & Development CAGR 5Y
30%
Over the last year, the Research & Development growth was 32%. The average annual Research & Development growth rates for UNITY Biotechnology Inc have been 34% over the past three years , 30% over the past five years .
